Syphilis Rapid Test
The Swiss Mediscan Syphilis Rapid Screen Test (RST) is a qualitative test for the detection of antibodies to T. pallidum in human serum/plasma or whole blood.
The Swiss Mediscan Syphilis Rapid Test (RST) is a qualitative Syphilis test for the detection of Syphilis symptoms antibodies to T. pallidum in human serum/plasma or whole blood.
Venereal syphilis is a chronic disease caused by infection with the spirochaete bacterium Treponema pallidum. Infection with the systemic from the outset and disease is characterized by periods of quiescence (latency) after in excess of 20 years. These features, together with the fact that T. pallidum cannot be easily isolated in culture, mean that serological techniques play a major role in the screening of syphilis.
During early primary syphilis the first antibodies to appear are class IgM. IgG class antibodies do not reach significant titers until later in the primary phase. As the disease progresses into the secondary phase, T. pallidum antibodies of both IgM and IgG classes reach peak tiers. Thereafter T. pallidum IgG antibodies will persist indefinitely regardless of the course of the disease, whereas serum levels of T. pallidum IgM will vary in a manner, which is closely related to disease activity.
If a T. pallidum infection is allowed to progress into the late phase of the disease, serum IgM will remain demonstrable. However, following successful treatment serum IgM levels will decline, eventually to negativity. The rate of decline varies with the stage at which treatment is commenced, so that syphilis treated during the primary phase of the disease will a more rapid IgM decline than in the case of an infection treated at a late phase of the disease. Serum IgM levels will generally show at least fourfold decrease within 3-4 months following treatment. The time to complete negativity will depend upon the sensitivity of the assay in use, but is usually less than 24 months.